Physician

Mark H Fleischman, MD

According to 2025 Medicare claims, Mark Fleischman, MD (NPI: 1215975867) practices dermatology in the Kansas City, MO-KS market, with the plurality of this provider's patient population coming from Jackson, MO. This provider's primary affiliated billing organization is DERMATOLOGY AND SKIN CANCER SPECIALISTS, LLC (NPI: 1205880846; TIN: 861072868) and primary practice location at 64064-2301.

Fleischman's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,578 traditional Medicare patients, billed 13,604 HCPCS/CPT codes, and received $915,450 in Medicare payments. The top billing code was 17311 (Removal and microscopic exam of growth of head, neck, hands, feet, or genitals, 1-5 tissue blocks). Part D data shows 2,260 prescription claims across 1,175 beneficiaries totaling $32,981 in drug costs, led by Fluorouracil (Fluorouracil). Open Payments data shows 152 records totaling $415,478. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs did not follow a clear longitudinal pattern. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	1,326	10,296	$720,242
2016	1,374	10,077	$666,563
2017	1,451	10,262	$651,358
2018	1,589	10,831	$663,503
2019	1,547	11,349	$755,425
2020	1,469	9,793	$683,294
2021	1,780	12,338	$865,818
2022	1,583	11,961	$799,216
2023	1,562	12,117	$798,302
2024	1,578	13,604	$915,450

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	608	989	$32,476
2016	672	1,131	$26,988
2017	715	1,229	$31,949
2018	777	1,314	$34,282
2019	792	1,399	$29,187
2020	786	1,315	$29,178
2021	1,003	1,660	$122,467
2022	900	1,616	$31,200
2023	1,014	1,873	$33,473
2024	1,175	2,260	$32,981

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
17311	Removal and microscopic exam of growth of head, neck, hands, feet, or genitals, 1-5 tissue blocks	414	580	$414
11102	Biopsy of related skin growth, first growth	767	1,046	$65
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	1,344	1,964	$61
17000	Destruction of precancer skin growth, 1 growth	1,029	1,600	$37
17003	Destruction of precancer skin growth, 2-14 growths	825	5,449	$5

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Fluorouracil	Fluorouracil	95	2,773	$6,060
Cephalexin	Cephalexin	833	6,403	$4,738
Doxycycline Hyclate	Doxycycline Hyclate	359	3,525	$2,829
Ketoconazole	Ketoconazole	205	7,030	$2,557
Gentamicin Sulfate	Gentamicin Sulfate	94	2,234	$2,505

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	109	$2,910	E.R. Squibb & Sons, L.L.C.
Research Payments	Reported research-related payment or transfer-of-value amount.	43	$412,567	ABBVIE INC.
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Mark H. Fleischman, MD?

Tedicare shows public-source Medicare data for Mark H. Fleischman, MD (NPI 1215975867), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Mark H. Fleischman, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Mark H. Fleischman, MD?

Mark H. Fleischman, MD is linked to DERMATOLOGY AND SKIN CANCER SPECIALISTS, LLC (billing NPI 1205880846) in the available physician profile data.

Does Mark H. Fleischman, MD have Open Payments data?

Mark H. Fleischman, MD has 152 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.